Evidence map›Paper›PMID 29332155›Full record

ArticleParasitology research2018

Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria.

Ekpereonne Esu, Costanza Tacoli, Prabhanjan Gai, Nicole Berens-Riha, Michael Pritsch, Thomas Loescher, Martin Meremikwu

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Mapping Antimalarial Drug Resistance in Mozambique: A Systematic Review ofInternational journal of molecular sciences · 2024
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Global Analysis ofMolecules (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The genomic architecture of antimalarial drug resistance.Briefings in functional genomics · 2019
    Review
  17. Mutation Profile ofAntimicrobial agents and chemotherapy · 2019
    Article
  18. Increased Frequency ofMalaria research and treatment · 2019
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ekpereonne EsuCenter for International Health (CIH), Ludwig-Maximilians-Universität (LMU), Leopoldstraße 7, 80802, Munich, Germany. ekpereonneesu@gmail.com.
Costanza TacoliInstitute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Prabhanjan GaiInstitute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Nicole Berens-RihaDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Leopoldstrasse 5, 80802, Munich, Germany.
Michael PritschDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Leopoldstrasse 5, 80802, Munich, Germany.
Thomas LoescherDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Leopoldstrasse 5, 80802, Munich, Germany.
Martin MeremikwuDepartment of Paediatrics, College of Medical Sciences, University of Calabar, Calabar, Nigeria.
Ludwig-Maximilians-Universität München · DECharité - Universitätsmedizin Berlin · DEUniversity of Calabar · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfadoxine-pyrimethamine (SP) is the recommended drug for intermittent preventive treatment of malaria in pregnancy in most of sub-Saharan Africa. Resistance to SP is related to mutations in the dhfr and dhps gene of Plasmodium falciparum. This study determined the prevalence of Pfdhfr and Pfdhps polymorphisms found in asymptomatic pregnant women attending antenatal care in Calabar, Nigeria. From October 2013 to November 2014, asymptomatic pregnant women attending antenatal care clinics were enrolled after obtaining informed consent. Malaria diagnosis testing was done using thick and thin smears. Dried blood spot filter papers were collected. Parasite DNA was extracted from the filter papers using a chelex extraction. Extraction was followed by nested PCR and restriction enzyme digestion. P. falciparum infection was detected by microscopy in 7% (32/459) participants. Twenty-eight P. falciparum isolates were successfully genotyped. In the Pfdhfr gene, the triple mutation was almost fixed; S108N mutation was (100%), N51I (93%) and C59R mutations (93%), whereas the I164L mutation was absent. The prevalence of Pfdhps S436A, A437G, A581G and A613S mutations was 82.1% (23/28), 96.4% (27/28), 71.4% (20/28) and 71.4% (20/28) respectively. The K540E mutation was absent. The prevalence of the Pfdhfr triple mutation IRNI was 92.9% (26/28). The efficacy of SP as IPTp in Southeast Nigeria may be severely threatened. The continuous monitoring of SP molecular markers of resistance is required to assess thresholds. The evaluation of alternative preventive treatment strategies and drug options for preventing malaria in pregnancy may be necessary.

Indexed as

MutationAdultAntimalarialsDrug CombinationsFemaleGenotypeHumansMalaria, FalciparumMutation RateNigeriaPlasmodium falciparumPolymerase Chain ReactionPolymorphism, GeneticPregnancyPregnancy Complications, ParasiticProtozoan ProteinsAntimalarialsDHFR protein, Plasmodium falciparumDrug Combinationsfanasil, pyrimethamine drug combinationProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate DehydrogenaseAntenatal clinicMalariaMolecular markersSP resistance

Identifiers

PMID29332155
OpenAlexW2784046526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.